Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022
Objective: to perform a clinical and economic analysis of using drugs containing follitropin alfa as an active substance and to assess the impact of the studied drugs on the budget of the state healthcare system of the Russian Federation considering cost data for 2022 in the population of women with...
Saved in:
Main Authors: | D. G. Shchurov (Author), D. V. Blinov (Author), N. V. Bashmakova (Author), M. A. Polzikov (Author), A. S. Semikhin (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies
by: K. A. Perova, et al.
Published: (2022) -
Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)
by: Z. B. Barakhoeva, et al.
Published: (2018) -
Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment
by: Agostinetto Rita
Published: (2009) -
Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study
by: Welcker J, et al.
Published: (2010) -
Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France
by: Matthieu Lehmann, et al.
Published: (2024)